Switching to aflibercept 8 mg in exudative AMD

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This multicenter, retrospective study analyzes medical records from patients with exudative AMD who were switched to aflibercept 8 mg as part of routine care. It compares injection intervals, visit frequency, visual and anatomical outcomes, and safety before and after the switch over a 12-month period. The analysis uses data from Western France to identify factors associated with longer injection intervals and to assess real-world tolerability of the higher-dose formulation. Outcomes include visual acuity, central macular thickness, fluid status, and ocular adverse events. The study is observational and aims to generate hypotheses for future prospective testing.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adults (≥18 years) with exudative (neovascular) age-related macular degeneration
* Treated with intravitreal anti-VEGF therapy for more than 1 year
* Switched to aflibercept 8 mg before July 31, 2025
* Injection interval strictly less than 12 weeks prior to switch

Exclusion Criteria:

* High myopia (axial length \> 26 mm or spherical equivalent \< -6 diopters)
* Angioid streaks
* Moderate or severe diabetic retinopathy
* History of diabetic macular edema
* History of uveitis
* History of retinal vein occlusion (branch or central)
* History of pseudovitelliform macular dystrophy
* Patient under legal guardianship or curatorship
* Pregnant or breastfeeding women

Where it's running

• CHU Nantes - Ophthalmology Department
  Nantes, Nantes, France Recruiting

Study contacts

• Study coordinator: Jean Baptiste DUCLOYER, MD, PhD
• Email: jeanbaptiste.ducloyer@chu-nantes.fr
• Phone: 02 40 08 34 01

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ethical considerations of using gene therapy for exudative AMD

  This study tests how patients with exudative AMD feel about gene therapy and how much they want to participate in decisions about this surgically delivered, irreversible treatment.

  Recruiting Nantes University Hospital · Nantes, Nantes · NCT07004361

• Four-session focal shock wave therapy for vulvodynia in women

  This study looks at whether four weekly sessions of low-intensity focal shock wave therapy help women with vulvodynia in real-life clinical practice.

  Recruiting Nantes University Hospital · Nantes, Nantes · NCT07553715

• Reproducibility of Digital Bite Mark Overlays in Adults

  This study tests how consistently different people can create digital bite mark overlays from 3D dental scans in adults who need routine dental care.

  Recruiting Nantes University Hospital · Nantes, Nantes · NCT07552051

• Dental care for people living with HIV in Pays de la Loire

  This study looks at whether people living with HIV in Pays de la Loire need any special dental management based on their health data.

  Recruiting Nantes University Hospital · Nantes, Nantes · NCT07552038

• 68Ga-FAPI-46 PET imaging to stage ATTR-CM and spot progression

  This study tests whether a gallium-68 labeled FAPI PET scan can help stage transthyretin cardiac amyloidosis and identify patients whose disease is progressing.

  Recruiting Phase 2 Nantes University Hospital · Nantes · NCT07549841

• IL-1β blocker after pancreatic transplant to help prevent graft thrombosis

  This trial tests whether adding Anakinra right after pancreatic transplant is safe for patients to see if it helps protect the new pancreas.

  Recruiting Phase 1/2 Nantes University Hospital · Nantes and 1 other locations · NCT07503834

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.